As filed with the Securities and Exchange Commission on August 9, 2011

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

ENTEROMEDICS INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		48-1293684
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

2800 Patton Road

St. Paul, MN 55113

(Address, including zip code, of registrant’s principal executive offices)

 

 

ENTEROMEDICS INC. 2003 STOCK INCENTIVE PLAN

(Full title of the plan)

 

 

Greg S. Lea

Chief Financial Officer and Secretary

EnteroMedics Inc.

2800 Patton Road

St. Paul, MN 55113

(651) 634-3003

(Name, address and telephone number, including area code, of agent for service)

 

 

Indicate by check mark, whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer		¨		Accelerated Filer		¨
Non-accelerated filer		¨  (Do not check if a smaller reporting company)		Smaller Reporting Company		x

 

 

CALCULATION OF REGISTRATION FEE

 

Title of securities to be registered		Amount to be registered(1)		Proposed maximum offering price per share		Proposed maximum aggregate offering price		Amount of registration fee
Common Stock ($0.01 par value per share)		2,000,000		$2.17(2)		$4,340,000(2)		$504

(1)

Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers additional shares of EnteroMedics Inc. common stock that may become issuable in accordance with the adjustment and anti-dilution provisions of the EnteroMedics Inc. 2003 Stock Incentive Plan.

(2)	Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(h)(1) and (c) under the Securities Act, based on the average of the high and low sale prices of EnteroMedics Inc.’s common stock as reported on the NASDAQ Capital Market on August 8, 2011.

 

 

 

---

EXPLANATORY NOTE

This Registration Statement on Form S-8 of EnteroMedics Inc. (the “Company”) is being filed pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, to register an additional 2,000,000 shares of common stock, par value $0.01 per share, of the Company issuable pursuant to the Company’s 2003 Stock Incentive Plan (the “Plan”). These additional shares were authorized by an amendment to the Plan, which was approved by the stockholders at the Company’s annual meeting of stockholders on May 5, 2011. The remaining shares of common stock issuable under the Plan have been previously registered by Registration Statements on Form S-8 (Registration Nos. 333-149662, 333-159592 and 333-171244), which registration statements are hereby incorporated by reference.

---

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT 

Item 3. Incorporation of Documents by Reference.

The following documents and information, which EnteroMedics Inc. (the “Company”) has filed with the Securities and Exchange Commission (“SEC”), are hereby incorporated by reference into this Registration Statement on Form S-8:

 

1.

The Company’s Annual Report on Form 10-K for the year ended December 31, 2010;

 

2.

The Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2011 and June 30, 2011;

 

3.

The Company’s Current Reports on Form 8-K filed with the SEC on January 11, 2011, March 28, 2011, May 10, 2011, June 14, 2011 and July 8, 2011; and

 

4.

The description of the Company’s common stock contained in its Registration Statement on Form 8-A filed with the SEC on November 8, 2007, including any amendment or report filed for the purpose of updating such description.

All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, (excluding any portions thereof furnished under Items 2.02 or 7.01 of Form 8-K) subsequent to the date hereof and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities remaining unsold shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents.

Item 8. Exhibits.

 

5.1		Opinion of Dorsey & Whitney LLP.
23.1		Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
23.2		Consent of Dorsey & Whitney LLP (included in Exhibit 5.1 to this Registration Statement).
24.1		Power of Attorney (included on signature page to this Registration Statement).

---

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of St. Paul, State of Minnesota, on the 9th day of August, 2011.

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark B. Knudson and Greg S. Lea, and each of them, his true and lawful attorneys-in-fact and agents, each acting alone, with the powers of substitution and revocation, for him and in his name, place and stead, in any and all capacities, to sign a Registration Statement on Form S-8, and any and all amendments (including post-effective amendments) thereto, relating to the issuance of shares of common stock of EnteroMedics Inc. pursuant to the EnteroMedics Inc. 2003 Stock Incentive Plan and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all such attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature		Title		Date
/s/ Mark B. Knudson, Ph.D.		President and Chief Executive Officer, Chairman and Director		August 9, 2011
Mark B. Knudson, Ph.D.		(principal executive officer)
/s/ Greg S. Lea		Senior Vice President and Chief Financial Officer		August 9, 2011
Greg S. Lea		(principal financial and accounting officer)
/s/ Luke Evnin, Ph.D.		Director		August 9, 2011
Luke Evnin, Ph.D.
/s/ Catherine Friedman		Director		August 9, 2011
Catherine Friedman
/s/ Carl Goldfischer, M.D.		Director		August 9, 2011
Carl Goldfischer, M.D.
/s/ Bobby I. Griffin		Director		August 9, 2011
Bobby I. Griffin

---

/s/ Anthony P. Jansz		Director		August 9, 2011
Anthony P. Jansz
/s/ Paul H. Klingenstein		Director		August 9, 2011
Paul H. Klingenstein
/s/ Nicholas L. Teti, Jr.		Director		August 9, 2011
Nicholas L. Teti, Jr.
/s/ Jon T. Tremmel		Director		August 9, 2011
Jon T. Tremmel

---

EXHIBIT INDEX

 

Exhibit No.		Description
5.1		Opinion of Dorsey & Whitney LLP.
23.1		Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
23.2		Consent of Dorsey & Whitney LLP (included in Exhibit 5.1 to this Registration Statement).
24.1		Power of Attorney (included on signature page to this Registration Statement).

Exhibit 5.1

[Letterhead of Dorsey & Whitney LLP]

August 9, 2011

EnteroMedics Inc.

2800 Patton Road

St. Paul, MN 55113

Re:    Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to EnteroMedics Inc., a Delaware corporation (the “Company”), in connection with the registration under the Securities Act of 1933, as amended, on a registration statement on Form S-8 (the “Registration Statement”) of an aggregate of 2,000,000 shares of the Company’s common stock, $0.01 par value per share (the “Shares”), issuable under the EnteroMedics Inc. 2003 Stock Incentive Plan (the “Plan”).

We have examined such documents and have reviewed such questions of law as we have considered necessary and appropriate for the purposes of this opinion. In rendering our opinion set forth below, we have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed the legal capacity for all purposes relevant hereto of all natural persons. As to questions of fact material to our opinion, we have relied upon certificates of officers of the Company and of public officials.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance, delivery and payment therefor in accordance with the terms of the Plan, and any relevant agreements thereunder, will be validly issued, fully paid and nonassessable.

Our opinion expressed above is limited to the Delaware General Corporation Law.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. The foregoing opinion is being furnished to you solely for your benefit and may not be relied upon by, nor may copies be delivered to, any other person without our prior written consent.

 

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 7, 2011, relating to the consolidated financial statements of EnteroMedics Inc. and subsidiary (the “Company”) (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the January 1, 2009 adoption of new authoritative accounting guidance regarding the financial reporting for outstanding equity-linked financial instruments), appearing in the Annual Report on Form 10-K of the Company for the year ended December 31, 2010.

 

/s/ Deloitte & Touche LLP

Minneapolis, Minnesota

August 5, 2011